Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes

References

• Adamsson I, Edlund C, Nord CE. (2000). Microbial ecology and treatment of Helicobacter pylori infections: review. J Chemother 12:5–16.
   PubMed Web of Science ®Google Scholar
• Andersson T, Miners JO, Veronese ME, Birkett DJ. (1994). Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37:597–604.
   PubMed Web of Science ®Google Scholar
• Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ. (1993). Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521–530.
   PubMed Web of Science ®Google Scholar
• Cederberg C, Andersson T, Skånberg I. (1989). Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl 166:33–40; discussion 41.
   PubMedGoogle Scholar
• Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, Bertilsson L. (1995). Interphenotype differences in disposition and effect on gastrin levels of omeprazole–suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39:511–518.
   PubMed Web of Science ®Google Scholar
• Chang TK, Waxman DJ. (2006). Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 38:51–73.
   PubMed Web of Science ®Google Scholar
• Chen Y, Goldstein JA. (2009). The transcriptional regulation of the human CYP2C genes. Curr Drug Metab 10:567–578.
   PubMed Web of Science ®Google Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. (1994a). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422.
   PubMed Web of Science ®Google Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994b). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598.
   PubMed Web of Science ®Google Scholar
• de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. (1995). Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58:404–411.
   PubMed Web of Science ®Google Scholar
• Fujisawa K, Watanabe Y, Kimura K. (1980). Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Med J 23:754.
   Google Scholar
• Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. (1998). Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129:1027–1030.
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. (2005). Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20:153–167.
   PubMedGoogle Scholar
• González HM, Romero EM, Chavez Tde J, Peregrina AA, Quezada V, Hoyo-Vadillo C. (2002). Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci 780:459–465.
   PubMedGoogle Scholar
• Handschin C, Meyer UA. (2003). Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 55:649–673.
   PubMed Web of Science ®Google Scholar
• Hattori T, Ikematsu S, Koito A, Matsushita S, Maeda Y, Hada M, Fujimaki M, Takatsuki K. (1989). Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS. Antiviral Res 11:255–261.
   PubMed Web of Science ®Google Scholar
• He JX, Akao T, Nishino T, Tani T. (2001). The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang. Biol Pharm Bull 24:1395–1399.
   PubMedGoogle Scholar
• Jeong HG, You HJ, Park SJ, Moon AR, Chung YC, Kang SK, Chun HK. (2002). Hepatoprotective effects of 18beta-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmacol Res 46:221–227.
   PubMed Web of Science ®Google Scholar
• Mu Y, Zhang J, Zhang S, Zhou HH, Toma D, Ren S, Huang L, Yaramus M, Baum A, Venkataramanan R, Xie W. (2006). Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther 316:1369–1377.
   PubMed Web of Science ®Google Scholar
• Paolini M, Pozzetti L, Sapone A, Cantelli-Forti G. (1998). Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases. Life Sci 62:571–582.
   PubMed Web of Science ®Google Scholar
• Paolini M, Barillari J, Broccoli M, Pozzetti L, Perocco P, Cantelli-Forti G. (1999). Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes. Cancer Lett 145:35–42.
   PubMed Web of Science ®Google Scholar
• Regårdh CG. (1986). Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol Suppl 118:99–104.
   PubMedGoogle Scholar
• Shibata S. (2000). A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 120:849–862.
   PubMed Web of Science ®Google Scholar
• Shu Y, Wang LS, Xiao WM, Wang W, Huang SL, Zhou HH. (2000). Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone. Acta Pharmacol Sin 21:753–758.
   PubMed Web of Science ®Google Scholar
• Takeda S, Ishthara K, Wakui Y, Amagaya S, Maruno M, Akao T, Kobashi K. (1996). Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J Pharm Pharmacol 48:902–905.
   PubMed Web of Science ®Google Scholar
• van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. (1998). Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 12:199–205.
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. (2006). Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 41:1087–1094.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Guengerich FP, Branch RA. (1989). Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53–76.
   PubMed Web of Science ®Google Scholar
• Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH. (1997). Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281:604–609.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. (1997). Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434–442.
   PubMed Web of Science ®Google Scholar
• Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. (2004). Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 14:841–850.
   PubMedGoogle Scholar
• Zhou H-H. (2003). Pharmacogenetics. Beijing: People’s Military Medical Press, p. 61–83.
   Google Scholar